Trump's demand to make the data public comes amid escalating divisions between the Centers for Disease Control and Prevention ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

A new group formed by top drug manufacturers is seeking to stop the expansion of Medicare drug price negotiations, lobbying ...

OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology for evaluation of safety and efficacy in Cancer.

Faster review times could leave drugmakers vulnerable to litigation, while new Trump administration priorities add more ...

If the trend holds, IQVIA expects 2025 deal volume between Chinese and multinational companies to easily eclipse the 100 ...

U.S. pharma bounced back in Q2, and in this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy ...

Glenmark Pharma’s US arm will launch Eribulin Mesylate Injection, a complex generic for breast cancer treatment, in025.

Two Chicago companies are merging to provide commercialization services that connect Big Pharma to payers and patients.

Recursion Pharmaceuticals (RXRX 0.02%), a biotech company focused on artificial intelligence (AI), went public in April 2021. This was before ChatGPT, before AI became the hottest ...